- Home
- GALT vs SWKH Comparison
GALT vs SWKH Comparison
Compare GALT & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GALT | SWKH |
|---|---|---|
| Founded | 2000 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Financial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.7M | 205.9M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | GALT | SWKH |
|---|---|---|
| Price | $3.54 | $17.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $8.50 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 510.8K | 8.9K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 120.89 |
| EPS | N/A | ★ 1.85 |
| Revenue | N/A | ★ $40,149,000.00 |
| Revenue This Year | N/A | $52.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.44 |
| Revenue Growth | N/A | ★ 62.38 |
| 52 Week Low | $1.11 | $13.17 |
| 52 Week High | $7.13 | $20.49 |
Technical Indicators
Market Signals| Indicator | GALT | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 42.75 | 56.34 |
| Support Level | $2.93 | $17.10 |
| Resistance Level | $3.27 | $17.63 |
| Average True Range (ATR) | 0.29 | 0.24 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 43.79 | 70.49 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.